Abstract
The prescribing of isotretinoin in male patients has become a hot topic of debate in the UK after an independent report from the UK Commission on Human Medicines in October 2023, which resulted in new safety guidance to encourage stricter monitoring of this cohort. We reviewed patients in a tertiary hospital in the UK where an online system has been monitoring genital side-effects and mood for the past 3 years, before this new safety guidance.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
